Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.


An antibody that reacts with the cells, tissues, or native proteins of the individual in which it is produced.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


n, pl -bodies
(Biochemistry) an antibody reacting with an antigen that is a part of the organism in which the antibody is formed
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014


(ˌɔ toʊˈæn tɪˌbɒd i, -ˈæn ti-)

n., pl. -bod•ies.
an antibody that an organism produces against any of its own components.
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.autoantibody - an antibody acting against tissues of the organism that produces it
rheumatoid factor - autoantibody that is usually present in the serum of people with rheumatoid arthritis
antibody - any of a large variety of proteins normally present in the body or produced in response to an antigen which it neutralizes, thus producing an immune response
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
It also varies in different geographic regions and is known to be higher in regions with higher iodine intake.6,7 The aim of this study was to evaluate the thyroid autoantibody profile in Type-1 diabetic patients and the Influence of the presence of thyroid autoimmune abnormalities on the control of diabetes in group of Iraqi pediatric patients with Type-I D.M.
As a member of the consortium, Sengenics aims to further accelerate the identification and commercialisation of autoantibody biomarkers for early diagnosis of cancer and autoimmune diseases as well as development of new companion diagnostics tests.
Sole thrombocyte replacement is not curable because the autoantibody presence persists.
"We are providing the first snapshot of autoantibody development in lupus patients by developing a novel detection method using a top-down mass spectrometry approach for identifying disease-specific autoantibodies quickly," said Wu, assistant professor, Department of Chemistry and Biochemistry, OU College of Arts and Sciences.
The discovery of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) has led to the proposal of a serologic approach to complement the Bohan and Peter classification system, as significantly associations of MSAs with clinical features were observed.[6] Certainly, the addition of autoantibody profiles, characteristic histopathologic features, and magnetic resonance imaging (MRI) could significantly strengthen the current criteria and better define these disorders.[7],[8],[9],[10],[11]
It will be placebo-controlled and will evaluate the efficacy of a 10 mg/kg dose of efgartigimod in gMG patients, including both acetylcholine receptor (AChR) autoantibody positive and AChR autoantibody negative patients whose disease is driven primarily by MuSK and LRP4 autoantibodies, over a period of 26 weeks.
The researchers identified a combination of 10 autoantibody biomarkers that, as a panel, displayed a sensitivity, specificity, and an area under the curve of 79 percent, 84 percent, and 0.828, respectively, for primary melanoma detection.
The placebo-controlled 26-week trial is expected to evaluate the efficacy of a 10 mg/kg dose of efgartigimod in approximately 150 gMG patients, including both AChR autoantibody positive and AChR autoantibody negative patients.
ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset.
Totally 168 samples were considered as rare autoantibody. Rare patterns were consisted of 49 (0.49%) midbody, 29 (0.29%) centriole, 20 (0.20%) spindle fibers, 21 (0.21%) anti-golgi, 37 (0.37%) anti-actin, 3 (0.03%) rod and rings, and 9 (0.09%) PCNA (proliferating cell nuclear antigen)-like (Table 1).
ImmunoQure and Servier have established an exclusive global partnership for the development of a therapeutic autoantibody neutralizing interferon-alpha.
Interstitial lung disease was more common in patients from both cohorts with this autoantibody compared with patients without these antibodies.